Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone

By WebmasterJanuary 13, 2015November 1st, 2024No Comments

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase
One Study of Novel NMDA Receptor Antagonist d-Methadone
Read more here

Previous PostMerganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Next PostQR Pharma Announces the Appointment of New Chairman and New Board Member